Kiadis Pharma BV, the Netherlands-based cell therapy company, has appointed Jeroen Rovers as its chief medical officer to help oversee the clinical development of its lead product for late-stage blood cancers. Dr Rovers was most recently CSO at Ceronco Biosciences BV and has also been a consultant to Kiadis. He has also worked as director of clinical development and business development at Organon, which was acquired by Schering-Plough in 2007 and is now part of Merck & Co Inc.
Kiadis announced the appointment on 3 September 2014.
Copyright 2014 Evernow Publishing Ltd